Cargando…
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients w...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064995/ https://www.ncbi.nlm.nih.gov/pubmed/21461386 http://dx.doi.org/10.1155/2011/913094 |
_version_ | 1782200937013575680 |
---|---|
author | Campsen, Jeffrey Zimmerman, Michael A. Mandell, Susan Kaplan, Maria Kam, Igal |
author_facet | Campsen, Jeffrey Zimmerman, Michael A. Mandell, Susan Kaplan, Maria Kam, Igal |
author_sort | Campsen, Jeffrey |
collection | PubMed |
description | Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls. |
format | Text |
id | pubmed-3064995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30649952011-03-31 A Decade of Experience Using mTor Inhibitors in Liver Transplantation Campsen, Jeffrey Zimmerman, Michael A. Mandell, Susan Kaplan, Maria Kam, Igal J Transplant Research Article Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls. Hindawi Publishing Corporation 2011 2011-03-15 /pmc/articles/PMC3064995/ /pubmed/21461386 http://dx.doi.org/10.1155/2011/913094 Text en Copyright © 2011 Jeffrey Campsen et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Campsen, Jeffrey Zimmerman, Michael A. Mandell, Susan Kaplan, Maria Kam, Igal A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title_full | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title_fullStr | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title_full_unstemmed | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title_short | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
title_sort | decade of experience using mtor inhibitors in liver transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064995/ https://www.ncbi.nlm.nih.gov/pubmed/21461386 http://dx.doi.org/10.1155/2011/913094 |
work_keys_str_mv | AT campsenjeffrey adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT zimmermanmichaela adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT mandellsusan adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT kaplanmaria adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT kamigal adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT campsenjeffrey decadeofexperienceusingmtorinhibitorsinlivertransplantation AT zimmermanmichaela decadeofexperienceusingmtorinhibitorsinlivertransplantation AT mandellsusan decadeofexperienceusingmtorinhibitorsinlivertransplantation AT kaplanmaria decadeofexperienceusingmtorinhibitorsinlivertransplantation AT kamigal decadeofexperienceusingmtorinhibitorsinlivertransplantation |